Author Archives: piomat
Osivax Raises €32M to Develop Universal Coronavirus and Influenza Vaccines
Osivax secures $36M in grant, equity funding for flu, coronavirus vaccine programs
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Top line results expected by the first quarter of 2021 —Lyon, France – April 09, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focusing on the development of a universal influenza vaccine candidate, announced today that it completed …
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate — Phase 2a clinical trial on 300 healthy volunteers run under US IND —Lyon, France – January 21, 2020 – OSIVAX, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, enrolled the first participant in …
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate Lyon, France – December 5, 2019 – Osivax announced today that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to further advance the development …
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate— Linda Lebon joins as Chief Regulatory Officer —— Florian Sourd joins as VP Finance — Lyon, France – October 30th, 2019 – Osivax announced today the appointment of Linda Lebon as Chief Regulatory Officer and Florian Sourd as VP …
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate– Full safety and immunogenicity results expected for end 2019 — Lyon, France – September 26th, 2019 – Osivax announced today that all participants have completed their final visit in the first-in-human clinical trial of OVX836 universal Influenza vaccine …
